Status:
ENROLLING_BY_INVITATION
Protective Effect of Probacine Against Negative Gut Metabolism and Organ Dysfunction After Cardiovascular Surgery (PANDA IV)
Lead Sponsor:
Nanjing Medical University
Collaborating Sponsors:
Shanghai East Hospital of Tongji University
West China Hospital
Conditions:
Cardiovascular Disease
Cardiopulmonary Bypass
Eligibility:
All Genders
18-90 years
Phase:
NA
Brief Summary
Cardiovascular diseases (CVDs) continue to be the primary cause of illness and death globally, emphasizing the pressing requirement for efficient prevention methods. Recent studies indicate that the g...
Eligibility Criteria
Inclusion
- Adult men and women;
- Cardiovascular surgery;
- Agree to participate in the study and sign the informed consent form.
Exclusion
- Pregnant women;
- Patients with preexisting psychotic disorders;
- Decline to participate in the study.
Key Trial Info
Start Date :
January 1 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2026
Estimated Enrollment :
500 Patients enrolled
Trial Details
Trial ID
NCT04444362
Start Date
January 1 2025
End Date
December 31 2026
Last Update
January 6 2026
Active Locations (5)
Enter a location and click search to find clinical trials sorted by distance.
1
Beijing Anzhen Hospital
Beijing, Beijing Municipality, China
2
The First Affiliated Hospital of Guangzhou Medical University
Guangzhou, Guangdong, China
3
The First Affiliated Hospital of Nanjing Medical University
Nanjing, Jiangsu, China, 210029
4
West China Hospital of Sichuan University
Chengdu, Sichuan, China